Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

News SummaryMost relevantAll newsSector newsTweets 

Hikma trims full year revenue forecast on Advair U.S. launch delay

share with twitter share with LinkedIn share with facebook
share via e-mail
05/19/2017 | 09:32am CEST

Drugmaker Hikma Pharmaceuticals Plc on Friday lowered its revenue forecast for the full year to reflect a delay in the launch of its generic asthma drug, after U.S. regulators denied approval citing "major" issues with the application.

Shares of the company fell as much 7.47 percent to 1,573 pence, the lowest since May, 2014. They were the top loser on the FTSE 100 bluechip index and the pan-European Stoxx 600 index.

Hikma now expects full-year revenue to be in the range of $2.0 billion-$2.1 billion at constant currency, down from its earlier forecast of $2.2 billion (1.7 billion pounds).

Earlier this month, the company said approval for its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair was unlikely in 2017.

Hikma and its partner Vectura Group Plc are in a race with Mylan to launch the first U.S. generic copy of Advair. The FDA has already delayed approval of Mylan's version.

Hikma on Friday lowered its 2017 revenue forecast for its generics business to $670 million, down from its earlier forecast of $800 million.

"This assumes we do not launch our generic version of Advair Diskus in 2017 and reflects the intensifying competitive environment in the U.S.," the company said in a statement.

Hikma maintained its full-year revenue estimate for its injectables unit at a range of $800 million-$825 million, with core operating margin seen in the high 30s.

(Reporting by Sanjeeban Sarkar and Tenzin Pema in Bengaluru; Editing by Sunil Nair)

share with twitter share with LinkedIn share with facebook
share via e-mail
10:41a GLAXOSMITHKLINE : 15.9% Potential Upside Indicated by Berenberg
05/25 GLAXOSMITHKLINE : New Malaria Study Findings Reported from GlaxoSmithKline plc (..
05/25 GLAXOSMITHKLINE : Data on Pharmaceutical Science Described by Researchers at Gla..
05/25 GLAXOSMITHKLINE : Study Data from GlaxoSmithKline plc Provide New Insights into ..
05/25 GLAXOSMITHKLINE : New Vaccines Findings Reported from GlaxoSmithKline plc (Struc..
05/25 GLAXOSMITHKLINE : Recent Research from GlaxoSmithKline plc Highlight Findings in..
05/25 GLAXOSMITHKLINE : Recent Research from GlaxoSmithKline plc Highlight Findings in..
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 GLAXOSMITHKLINE : Hikma sales blow
05/22 WILSON THERAPEUTICS : Strengthens its Board of Directors by the Appointments of ..
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/25 FDA drug approvals rebound from last year, up over 100% yoy
05/25 FDA chief says agency needs to play a role in constraining drug prices by eas..
05/22 'Safer' Dividend Healthcare Dog's 55% Top Gain Equals Sum Of Four Tailing It ..
05/22 Healthcare Dogs See Psychemedics Tops By Gains In May
05/22 Tracking Tweedy Browne Portfolio - Q1 2017 Update
Financials ( GBP)
Sales 2017 30 028 M
EBIT 2017 8 332 M
Net income 2017 4 381 M
Debt 2017 13 977 M
Yield 2017 4,87%
P/E ratio 2017 19,22
P/E ratio 2018 16,67
EV / Sales 2017 3,16x
EV / Sales 2018 3,03x
Capitalization 80 818 M
More Financials
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 17,7  GBP
Spread / Average Target 8,0%
Consensus details
EPS Revisions
More Estimates Revisions
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Roy Malcolm Anderson Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.69%341 901
ROCHE HOLDING LTD.14.88%236 581
NOVARTIS AG6.75%211 457
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results